BioCardia
Overview
BioTherapeutics: CardiAMP Therapy
BioTherapeutics: CardiALLO Therapy
Enabling Devices: Helix System
Enabling Devices: Morph Products

Product Pipeline Overview

BioCardia is developing two comprehensive biotherapeutic candidates for cardiac regenerative medicine, with an initial focus on heart failure resulting from a heart attack:

  • CardiAMP autologous minimally processed bone marrow cells (a patient’s own cells)
  • CardiALLO allogenic culture expanded mesenchymal stem cells derived from bone marrow  (donor-derived)  

Both programs have demonstrated safety and efficacy in clinical studies. They provide compelling and synergistic approaches to replicating the natural response of bone marrow cells to cardiac injury. CardiAMP harnesses the potential of autologous minimally processed bone marrow cells, using a companion diagnostic to identify patients most likely to benefit from the therapy.  CardiALLO utilizes younger universal donor mesenchymal stem cells and may be appropriate for patients who are not optimal candidates for the CardiAMP therapy. 
                  
The company currently has several commercial devices, which are used as part of its biotherapeutic solutions, and can be used for other interventional procedures. The Helix transendocardial delivery system is also being used by several clinical partners in biotherapeutic clinical trials.



Click on the title of any program below for more information

pipeline chart

enabling devices